{"id":"https://openalex.org/W2967066402","doi":"https://doi.org/10.1111/jdv.15862","title":"Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate\u2010to\u2010severe psoriasis: a pooled analysis of two randomized controlled trials","display_name":"Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate\u2010to\u2010severe psoriasis: a pooled analysis of two randomized controlled trials","publication_year":2019,"publication_date":"2019-08-13","ids":{"openalex":"https://openalex.org/W2967066402","doi":"https://doi.org/10.1111/jdv.15862","mag":"2967066402","pmid":"https://pubmed.ncbi.nlm.nih.gov/31407394","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6899626"},"language":"en","primary_location":{"id":"doi:10.1111/jdv.15862","doi":"https://doi.org/10.1111/jdv.15862","is_oa":true,"landing_page_url":"https://doi.org/10.1111/jdv.15862","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdv.15862","source":{"id":"https://openalex.org/S137740113","display_name":"Journal of the European Academy of Dermatology and Venereology","issn_l":"0926-9959","issn":["0926-9959","1468-3083"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the European Academy of Dermatology and Venereology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdv.15862","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5080237247","display_name":"Andrew Blauvelt","orcid":"https://orcid.org/0000-0002-2633-985X","observed_orcids":["https://orcid.org/0000-0002-2633-985X"]},"institutions":[{"id":"https://openalex.org/I4210127914","display_name":"Oregon Medical Research Center","ror":"https://ror.org/03m027021","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210127914"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"A. Blauvelt","raw_affiliation_strings":["Oregon Medical Research Center, Portland, OR, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oregon Medical Research Center, Portland, OR, USA","institution_ids":["https://openalex.org/I4210127914"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080223253","display_name":"Howard L. Sofen","orcid":"https://orcid.org/0000-0001-7789-6915","observed_orcids":["https://orcid.org/0000-0001-7789-6915"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H. Sofen","raw_affiliation_strings":["Department of Medicine (Dermatology), UCLA, Los Angeles, CA, USA"],"raw_orcid":"https://orcid.org/0000-0001-7789-6915","affiliations":[{"raw_affiliation_string":"Department of Medicine (Dermatology), UCLA, Los Angeles, CA, USA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008286260","display_name":"Kim Alexander Papp","orcid":"https://orcid.org/0000-0001-9557-3642","observed_orcids":["https://orcid.org/0000-0001-9557-3642"]},"institutions":[{"id":"https://openalex.org/I4210122653","display_name":"Probity Medical Research","ror":"https://ror.org/0222df516","country_code":"CA","type":"facility","lineage":["https://openalex.org/I4210122653"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"K. Papp","raw_affiliation_strings":["Probity Medical Research, Waterloo, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Probity Medical Research, Waterloo, ON, Canada","institution_ids":["https://openalex.org/I4210122653"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006526834","display_name":"Melinda Gooderham","orcid":"https://orcid.org/0000-0001-8926-0113","observed_orcids":["https://orcid.org/0000-0001-8926-0113"]},"institutions":[{"id":"https://openalex.org/I4210087212","display_name":"SKiN Health","ror":"https://ror.org/005wzfh51","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I4210087212"]},{"id":"https://openalex.org/I4210122653","display_name":"Probity Medical Research","ror":"https://ror.org/0222df516","country_code":"CA","type":"facility","lineage":["https://openalex.org/I4210122653"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"M. Gooderham","raw_affiliation_strings":["Probity Medical Research, Waterloo, ON, Canada","Skin Centre for Dermatology, Peterborough, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Probity Medical Research, Waterloo, ON, Canada","institution_ids":["https://openalex.org/I4210122653"]},{"raw_affiliation_string":"Skin Centre for Dermatology, Peterborough, ON, Canada","institution_ids":["https://openalex.org/I4210087212"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000478173","display_name":"Stephen Keith Tyring","orcid":"https://orcid.org/0000-0002-3337-0580","observed_orcids":["https://orcid.org/0000-0002-3337-0580"]},"institutions":[{"id":"https://openalex.org/I919571938","display_name":"The University of Texas Health Science Center at Houston","ror":"https://ror.org/03gds6c39","country_code":"US","type":"education","lineage":["https://openalex.org/I919571938"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Tyring","raw_affiliation_strings":["Department of Dermatology, University of Texas Health Science Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, University of Texas Health Science Center, Houston, TX, USA","institution_ids":["https://openalex.org/I919571938"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100769640","display_name":"Yang Zhao","orcid":"https://orcid.org/0000-0003-4901-2216","observed_orcids":["https://orcid.org/0000-0003-4901-2216"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y. Zhao","raw_affiliation_strings":["Sun Pharmaceuticals, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sun Pharmaceuticals, Princeton, NJ, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110080429","display_name":"Simon Lowry","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Lowry","raw_affiliation_strings":["Sun Pharmaceuticals, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sun Pharmaceuticals, Princeton, NJ, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077123873","display_name":"Aaron B. Mendelsohn","orcid":"https://orcid.org/0000-0002-0560-1177","observed_orcids":["https://orcid.org/0000-0002-0560-1177"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Mendelsohn","raw_affiliation_strings":["Sun Pharmaceuticals, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sun Pharmaceuticals, Princeton, NJ, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110906169","display_name":"Jeffrey R. Parno","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Parno","raw_affiliation_strings":["Sun Pharmaceuticals, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sun Pharmaceuticals, Princeton, NJ, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5000572878","display_name":"Kristian Reich","orcid":"https://orcid.org/0000-0001-5248-4332","observed_orcids":["https://orcid.org/0000-0001-5248-4332"]},"institutions":[{"id":"https://openalex.org/I4210108711","display_name":"University Medical Center Hamburg-Eppendorf","ror":"https://ror.org/01zgy1s35","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I159176309","https://openalex.org/I4210108711"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"K. Reich","raw_affiliation_strings":["Dermatologikum Berlin Berlin Germany","Translational Research in Inflammatory Skin Diseases Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg\u2010Eppendorf Skinflammation<sup>\u00ae</sup> Center Hamburg Germany","Translational Research in Inflammatory Skin Diseases Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg\u2010Eppendorf Skinflammation\u00ae Center Hamburg Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dermatologikum Berlin Berlin Germany","institution_ids":[]},{"raw_affiliation_string":"Translational Research in Inflammatory Skin Diseases Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg\u2010Eppendorf Skinflammation<sup>\u00ae</sup> Center Hamburg Germany","institution_ids":["https://openalex.org/I4210108711"]},{"raw_affiliation_string":"Translational Research in Inflammatory Skin Diseases Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg\u2010Eppendorf Skinflammation\u00ae Center Hamburg Germany","institution_ids":["https://openalex.org/I4210108711"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5080237247"],"corresponding_institution_ids":["https://openalex.org/I4210127914"],"apc_list":{"value":3000,"currency":"USD","value_usd":3000},"apc_paid":{"value":3000,"currency":"USD","value_usd":3000},"fwci":2.6171,"has_fulltext":true,"cited_by_count":61,"citation_normalized_percentile":{"value":0.90221192,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"33","issue":"12","first_page":"2305","last_page":"2312"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tildrakizumab","display_name":"tildrakizumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/plaque-psoriasis","display_name":"plaque psoriasis","score":0.9210000038146973},{"id":"https://openalex.org/keywords/moderate-to-severe-psoriasis","display_name":"moderate-to-severe psoriasis","score":0.8700000047683716},{"id":"https://openalex.org/keywords/pasi-improvement","display_name":"PASI improvement","score":0.7599999904632568},{"id":"https://openalex.org/keywords/dermatology-life-quality-index","display_name":"Dermatology Life Quality Index","score":0.8920000195503235},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.9739999771118164},{"id":"https://openalex.org/keywords/long-term-efficacy","display_name":"long-term efficacy","score":0.6819999814033508},{"id":"https://openalex.org/keywords/dose-comparison","display_name":"dose comparison","score":0.6039999723434448},{"id":"https://openalex.org/keywords/treatment-response-over-time","display_name":"treatment response over time","score":0.36800000071525574},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.41600000858306885},{"id":"https://openalex.org/keywords/serious-adverse-events","display_name":"serious adverse events","score":0.4779999852180481}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.951204240322113},{"id":"https://openalex.org/C2777011040","wikidata":"https://www.wikidata.org/wiki/Q390643","display_name":"Psoriasis Area and Severity Index","level":3,"score":0.812090277671814},{"id":"https://openalex.org/C2776173921","wikidata":"https://www.wikidata.org/wiki/Q25326609","display_name":"Dermatology Life Quality Index","level":3,"score":0.7586379051208496},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.6377021670341492},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6000487208366394},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.5551881790161133},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.478710412979126},{"id":"https://openalex.org/C3020604521","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Plaque psoriasis","level":3,"score":0.45089957118034363},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4100210666656494},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.22234869003295898},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010919","descriptor_name":"Placebos","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":5,"locations":[{"id":"doi:10.1111/jdv.15862","doi":"https://doi.org/10.1111/jdv.15862","is_oa":true,"landing_page_url":"https://doi.org/10.1111/jdv.15862","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdv.15862","source":{"id":"https://openalex.org/S137740113","display_name":"Journal of the European Academy of Dermatology and Venereology","issn_l":"0926-9959","issn":["0926-9959","1468-3083"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the European Academy of Dermatology and Venereology","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5871871","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6899626","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmid:31407394","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/31407394","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the European Academy of Dermatology and Venereology : JEADV","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:6899626","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6899626/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"J Eur Acad Dermatol Venereol","raw_type":"Text"},{"id":"pmh:oai:escholarship.org:ark:/13030/qt2bn3x09q","doi":null,"is_oa":true,"landing_page_url":"https://escholarship.org/uc/item/2bn3x09q","pdf_url":null,"source":{"id":"https://openalex.org/S4306400115","display_name":"eScholarship (California Digital Library)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2801248553","host_organization_name":"California Digital Library","host_organization_lineage":["https://openalex.org/I2801248553"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal of the European Academy of Dermatology and Venereology, vol 33, iss 12","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1111/jdv.15862","doi":"https://doi.org/10.1111/jdv.15862","is_oa":true,"landing_page_url":"https://doi.org/10.1111/jdv.15862","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdv.15862","source":{"id":"https://openalex.org/S137740113","display_name":"Journal of the European Academy of Dermatology and Venereology","issn_l":"0926-9959","issn":["0926-9959","1468-3083"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the European Academy of Dermatology and Venereology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2967066402.pdf","grobid_xml":"https://content.openalex.org/works/W2967066402.grobid-xml"},"referenced_works_count":14,"referenced_works":["https://openalex.org/W65111514","https://openalex.org/W1754228489","https://openalex.org/W1968179324","https://openalex.org/W1968405676","https://openalex.org/W1973354423","https://openalex.org/W2012581664","https://openalex.org/W2087624875","https://openalex.org/W2103120331","https://openalex.org/W2107432039","https://openalex.org/W2160630176","https://openalex.org/W2418506270","https://openalex.org/W2589858067","https://openalex.org/W2623888527","https://openalex.org/W2786492839"],"related_works":["https://openalex.org/W2901315913","https://openalex.org/W3129022701","https://openalex.org/W3194908373","https://openalex.org/W4297002146","https://openalex.org/W7034314365","https://openalex.org/W2953295625","https://openalex.org/W4402109477","https://openalex.org/W2954786324","https://openalex.org/W4393320899","https://openalex.org/W4388128802"],"abstract_inverted_index":{"BACKGROUND:":[0],"Two":[1],"randomized":[2],"controlled":[3],"trials":[4],"(reSURFACE":[5],"1":[6,80],"and":[7,39,56,81,84,102,107,130,144,149,154,167,186,248,281],"2)":[8],"have":[9],"demonstrated":[10],"the":[11,28,35,128,133,147,157,212],"effectiveness":[12],"of":[13,37,44,52,215,238],"tildrakizumab,":[14],"a":[15,286],"high-affinity,":[16],"humanized,":[17],"IgG1\u03ba,":[18],"anti-interleukin-23":[19],"monoclonal":[20],"antibody,":[21],"for":[22,94,118,233],"treating":[23],"moderate-to-severe":[24],"plaque":[25],"psoriasis":[26],"in":[27,47,127,132,146,156,243],"first":[29],"28":[30,75,177,209],"weeks.":[31],"OBJECTIVES:":[32],"To":[33],"examine":[34],"efficacy":[36],"tildrakizumab":[38,65,216,274],"its":[40],"impact":[41],"on":[42],"quality":[43],"life":[45],"(QoL)":[46],"patients":[48,202,239,261],"with":[49,64,171,188,262,304],"different":[50],"levels":[51],"week-28":[53,90,189,245],"Psoriasis":[54],"Area":[55],"Severity":[57],"Index":[58,111],"(PASI)":[59],"improvement.":[60,306],"METHODS:":[61],"Patients":[62,170,269],"treated":[63],"100":[66,264],"mg":[67,70],"or":[68,225,253],"200":[69],"from":[71,78],"baseline":[72],"to":[73,217,255,271,273,284],"week":[74,138,176,184,199,208,218,256,279,297],"were":[76,116,126,231],"pooled":[77],"reSURFACE":[79,82],"2":[83],"classified":[85],"into":[86],"five":[87],"mutually":[88],"exclusive":[89],"PASI":[91,97,105,161,172,190,196,204,221,246,263,287,300],"improvement":[92,106,197,222,301],"groups":[93],"each":[95,119],"dose:":[96],"0-49,":[98],"50-74,":[99,164],"75-89,":[100,165],"90-99":[101,166],"100.":[103],"Mean":[104],"Dermatology":[108],"Life":[109],"Quality":[110],"(DLQI)":[112],"0/1":[113,242,250],"over":[114,227],"time":[115],"examined":[117],"group.":[120],"RESULTS:":[121],"Of":[122],"1156":[123],"patients,":[124],"575":[125],"100-mg":[129,148],"578":[131],"200-mg":[134,158],"cohorts,":[135],"respectively.":[136,169],"At":[137],"28,":[139],"8.3%,":[140],"14.3%,":[141],"23.8%,":[142],"30.4%":[143],"23.1%":[145],"4.0%,":[150],"18.1%,":[151],"19.6%,":[152],"29.1%":[153],"29.3%":[155],"cohort":[159],"achieved":[160,240],"<":[162,173],"50,":[163],"100,":[168],"50":[174,206],"at":[175,207],"could":[178,275,291],"be":[179,276,292],"identified":[180,277,293],"as":[181,183,294,296],"early":[182,295],"8,":[185,280],"those":[187,282],"\u2265":[191,288],"90":[192,289],"had":[193,265],"approximately":[194],"50%":[195],"by":[198,278],"4.":[200,298],"Among":[201],"achieving":[203],">":[205],"who":[210],"continued":[211],"same":[213],"dose":[214],"52,":[219],"mean":[220],"was":[223,251],"maintained":[224,252],"improved":[226,254],"time.":[228],"Similar":[229],"results":[230],"observed":[232],"both":[234],"doses.":[235],"Higher":[236],"proportions":[237],"DLQI":[241,249,266],"higher":[244],"groups,":[247],"52.":[257],"However,":[258],"not":[259],"all":[260],"0/1.":[267],"CONCLUSION:":[268],"unlikely":[270],"respond":[272],"likely":[283],"achieve":[285],"response":[290],"Week-28":[299],"level":[302],"correlated":[303],"QoL":[305]},"counts_by_year":[{"year":2026,"cited_by_count":9},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":12},{"year":2022,"cited_by_count":15},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":1}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2019-08-22T00:00:00"}